165 related articles for article (PubMed ID: 25809175)
1. Labor costs and economic impact of a primary care clinical pharmacy service on postfracture care in postmenopausal women.
Irwin AN; Billups SJ; Heilmann RM
Pharmacotherapy; 2015 Mar; 35(3):243-50. PubMed ID: 25809175
[TBL] [Abstract][Full Text] [Related]
2. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
3. Impact of a pharmacist-directed intervention in postmenopausal women after fracture.
Heilmann RM; Friesleben CR; Billups SJ
Am J Health Syst Pharm; 2012 Mar; 69(6):504-9. PubMed ID: 22382482
[TBL] [Abstract][Full Text] [Related]
4. The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis.
Thompson M; Pasquale M; Grima D; Moehrke W; Kruse HP
Value Health; 2010; 13(1):46-54. PubMed ID: 19883401
[TBL] [Abstract][Full Text] [Related]
5. Prevention of adverse drug events and cost savings associated with PharmD interventions in an academic Level I trauma center: an evidence-based approach.
Hamblin S; Rumbaugh K; Miller R
J Trauma Acute Care Surg; 2012 Dec; 73(6):1484-90. PubMed ID: 23064610
[TBL] [Abstract][Full Text] [Related]
6. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
Brecht JG; Kruse HP; Felsenberg D; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2003; 23(4):93-105. PubMed ID: 15224498
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
[TBL] [Abstract][Full Text] [Related]
9. Actual versus projected cost avoidance for clinical pharmacy specialist-initiated medication conversions in a primary care setting in an integrated health system.
Kroner BA; Billups SJ; Garrison KM; Lyman AE; Delate T
J Manag Care Pharm; 2008 Mar; 14(2):155-63. PubMed ID: 18331117
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of two inexpensive postfracture osteoporosis interventions: results of a randomized trial.
Majumdar SR; Lier DA; Leslie WD
J Clin Endocrinol Metab; 2013 May; 98(5):1991-2000. PubMed ID: 23596140
[TBL] [Abstract][Full Text] [Related]
11. Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial.
Majumdar SR; Lier DA; Beaupre LA; Hanley DA; Maksymowych WP; Juby AG; Bell NR; Morrish DW
Arch Intern Med; 2009 Jan; 169(1):25-31. PubMed ID: 19139320
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women.
Mueller D; Gandjour A
Value Health; 2009; 12(8):1106-17. PubMed ID: 19706151
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis.
Mueller D; Gandjour A
Appl Health Econ Health Policy; 2011 Jul; 9(4):259-73. PubMed ID: 21682353
[TBL] [Abstract][Full Text] [Related]
15. Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.
Siris ES; Baim S; Nattiv A
Postgrad Med; 2010 Jan; 122(1):82-90. PubMed ID: 20107292
[TBL] [Abstract][Full Text] [Related]
16. Targeted estrogen/progesterone replacement therapy for osteoporosis: calculation of health care cost savings.
Clark AP; Schuttinga JA
Osteoporos Int; 1992 Jul; 2(4):195-200. PubMed ID: 1611225
[TBL] [Abstract][Full Text] [Related]
17. Effect of clinical pharmacist interventions on cost in an integrated health system specialty pharmacy.
Lankford C; Dura J; Tran A; Lam SW; Naelitz B; Willner M; Geyer K
J Manag Care Spec Pharm; 2021 Mar; 27(3):379-384. PubMed ID: 33645240
[No Abstract] [Full Text] [Related]
18. Health-related quality of life in economic evaluations for osteoporosis: whose values should we use?
Gabriel SE; Kneeland TS; Melton LJ; Moncur MM; Ettinger B; Tosteson AN
Med Decis Making; 1999; 19(2):141-8. PubMed ID: 10231076
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women.
Christensen PM; Brixen K; Gyrd-Hansen D; Kristiansen IS
Basic Clin Pharmacol Toxicol; 2005 May; 96(5):387-96. PubMed ID: 15853932
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility and budget impact analysis of primary prevention with alendronate of osteoporotic hip fractures in Catalonia.
Pueyo MJ; Larrosa M; Surís X; Garcia-Ruiz AJ
Reumatol Clin; 2012; 8(3):128-34. PubMed ID: 22421456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
